Skip to content
ppharmaranks
Menu
CompaniesProductsDrug classesConditionsBest by conditionTreatmentsInteraction checkerFood & medicinesWhat pharmacies payPill identifierMedicines & breastfeedingChildren’s dosage chartsDo medicines expire?Crushing & splitting pillsDrug recallsSupplementsSafety & lawsuitsGuidesA–ZHow we rate

New FDA drug approvals

Every genuinely new drug the FDA has approved since January 2025 — 35 of them, newest first. Generic approvals are excluded on purpose: most FDA approvals in any month are manufacturers getting permission to copy a molecule that already exists, which is not a new drug. This page lists only original applications.

Approved is not the same as available — or as better

Approval is permission to market a drug. The company still has to launch it, price it and get it stocked, and your insurer decides separately whether to cover it — months can pass. And newest is not best: a drug approved weeks ago is the one whose rare and long-term effects are least understood, because the trials behind it were smaller and shorter than real life. Priority Review, where we flag it, means the FDA aimed to finish its review in about six months instead of ten. It describes the review, not the medicine.

By the pharmaranks editorial teamReviewed against the FDA (Drugs@FDA & drug labels via openFDA) sourcesUpdated Jul 19, 2026How we research

We carry a rated page for 24 of these 35. Where we do not, we say so rather than showing a score — our ratings come from FDA recall-safety data, and a drug approved weeks ago has no such record to draw on.

Frequently asked questions

Does FDA approval mean I can get the drug now?

No. Approval is permission to market it — the company still has to launch it, set a price, and get it stocked, and insurers decide separately whether to cover it. Months can pass between the date on this page and a pharmacy being able to fill it. Some approved drugs are never launched at all.

What does Priority Review mean? Is the drug better?

It means the FDA aimed to complete its review in about six months rather than about ten, because the drug may offer a significant improvement where treatment is limited. It describes how fast the agency looked at the application — not how well the drug works, and not that it is safer. A Standard Review drug is not a second-rate one.

Why are generic drugs not on this list?

Because a generic approval is not a new drug. Most FDA approvals in any given month are abbreviated applications (ANDAs) from manufacturers seeking permission to make a copy of a molecule that already exists. This page lists only original applications — NDAs and BLAs — which is what makes a drug genuinely new.

Why do some entries not say what the drug treats?

Because the FDA label had not been published in openFDA when we last refreshed. That is normal for the newest approvals, and we would rather leave it blank than guess at an indication. Those entries fill in once the label appears.

Why do some new drugs have no rating here?

Our ratings are built from FDA recall-safety data, and a drug approved weeks ago has no such record — there is nothing to rate yet, and an early rating would be an artefact of having no data rather than a judgement about the drug. We say so rather than showing a placeholder score.

Is a newly approved drug better than an older one?

Not automatically. A new drug is one whose rare and long-term effects are least understood, because the trials that supported approval are smaller and shorter than real-world use. Some new approvals are genuine breakthroughs; others are a new formulation, a new dose or a new route of an existing molecule. What the drug treats and how it compares to what already exists is a conversation for a prescriber.

Sources

Approval dates and application types come from Drugs@FDA; indications are quoted from the FDA label where one has been published. Last refreshed Jul 10, 2026 or later. This is general reference information, not medical advice, and not a recommendation to take any drug.